Spanish-Filipino biopharmaceutical startup Ankar Pharma is working on a promising treatment for multiple sclerosis (MS). Dr. Ana Martinez, a professor and researcher at the Biological Research Center (CIB) of the Spanish National Council for Research (CSIC), explains that while there are several palliative treatments available on the market for MS, research and development should focus more on curative solutions to this debilitating disease.
The company’s leading pipeline product for MS, AP-1, is still in preclinical development but has already shown promising results. It has been noted to reduce the severity of clinical symptoms both in preventive treatment and in administration to a full-blown MS case. It has effective anti-inflammatory properties, can prevent oligodendrocyte damage and death, stimulate remyelinization, and can be administered orally.
Knowing the process for drug approval takes a decade to complete on average, Dr. Martinez founded the company to help speed up the drug development process and make reliable solutions available to MS patients sooner. Ankar Pharma works closely with several investors from Spain and the Philippines, and is headed by Jose Maria Olbes as Vice President of Business Development, and Jose D. Leviste as general counselor, to help grow the Philippines as a center for biotech research.
Ankar Pharma has just opened a crowdfunding initiative for the progression of AP-1 towards clinical trials. To find out how you can support upcoming research and help hasten drug development for MS patients, click here.